DNA · Healthcare
Ginkgo Bioworks Holdings Inc
27/100
Smart-money confidence1 of 3 sources positive
Weak — few signals
No standout activity across the feeds we track.
Hedge funds
36
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$457M
Industry
Biotechnology
Sector
Healthcare
Exchange
NYSE
About GINKGO BIOWORKS HOLDINGS INC
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also…
Who's behind the signal
Every informed buyer we can see on DNA, across all three feeds.
Hedge funds · 6
Tudor Investment (Paul Tudor Jones)
Increased +140%
AQR Capital Management
Increased +73%
Millennium Management (Englander)
Increased +898%
Viking Global Investors
Unchanged
Baillie Gifford & Co
Unchanged
D.E. Shaw & Co
Decreased −20%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
GINKGO BIOWORKS HOLDINGS INC isn't in the top-10 model right now, but 6 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
6
Investors
0
New positions
3
Increasing
1
Decreasing
2
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.2×
% of portfolio
0.0%
Position change
+140%
0.0% of Tudor Investment's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+73%
0.0% of AQR Capital Management's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+898%
0.0% of Millennium Management's portfolio
Trust weight: 1.5×
% of portfolio
0.1%
Position change
—
0.1% of Viking Global Investors's portfolio
Trust weight: 1.4×
% of portfolio
0.0%
Position change
—
0.0% of Baillie Gifford & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−20%
0.0% of D.E. Shaw & Co's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to GINKGO BIOWORKS HOLDINGS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell GINKGO BIOWORKS HOLDINGS INC or any security.
订阅每周更新
我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费，直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订